CYAD News and Press, Celyad SA From 08/06/20

Celyad Oncology (NASDAQ: CYAD ) : 1H Net loss of €16.6M. More news on: Celyad Oncology SA, Earnings news and commentary, Healthcare stocks news, , Read more ...

Interim analysis from alloSHRINK Phase 1 trial demonstrated mPFS of 3.9 months for mCRC patients with MSS disease treated with CYAD-101 following FOLFOX preconditioning; expansion cohort of alloSHRINK trial on-track to begin by fourth quarter 2020 Phase 1 dose-escalation trial for lead...

MONT-SAINT-GUIBERT, Belgium, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company...

IMV (NASDAQ: IMV ) +162%   rallies on COVID-19 vaccine progress. More news on: IMV Inc., VolitionRx Limited, INmune Bio, Inc., Stocks on the move, , Read more ...

The FDA has signed off on Celyad Oncology SA's (NASDAQ: CYAD ) IND for a Phase 1 clinical trial evaluating lead off-the-shelf short hairpin RNA-based allogeneic CAR-T candidate CYAD-211. More news on: Celyad Oncology SA, Healthcare stocks news, Stocks on the move, Read more ...

Phase 1 clinical trial evaluating the off-the-shelf anti-BCMA CAR T candidate CYAD-211 for the treatment of relapsed/refractory multiple myeloma (r/r MM) expected to begin by year-end 2020 CYAD-211 represents the company’s first allogeneic CAR T clinical candidate using shRNA t...

Nkarta (NASDAQ: NKTX ) had a big IPO, upsizing the number of shares sold to 14M from 10M. It also priced at $18 vs. the expected range of $16-$17. The offering raised $252M. More news on: Nkarta, Inc., Fate Therapeutics, Inc., CRISPR Therapeutics AG, Top stock market news, IPO News, Health...

Quick Take Nkarta ( NKTX ) intends to raise $150 million in an IPO of its common stock, according to an amended registration statement . The company is advancing a pipeline of drug candidates for the treatment of blood and other cancer indications. NKTX is still at preclinical stage of ...

Shareholders approve new name which better reflects the Company’s ambition to pioneer CAR T cell therapies for cancer MONT-SAINT-GUIBERT, Belgium, June 10, 2020 (GLOBE NEWSWIRE) -- Celyad SA (Euronext & Nasdaq: CYAD), clinical-stage biotechnology company focused on the dis...

Celyad Reports Positive Update on Non Gene Edited Allogeneic CAR-T Therapy Celyad ( CYAD ) announced update for its Phase 1 clinical trial alloSHRINK. The trial aims to assess the potential of its lead drug candidate CYAD-101 for patients suffering from metastatic colorectal cancer. It e...